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A chromosomal rearrangement in a child
with severe speech and language disorder
separates FOXP2 from a functional enhancer
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Abstract
Mutations of FOXP2 in 7q31 cause a rare disorder involving speech apraxia, accompanied by expressive and
receptive language impairments. A recent report described a child with speech and language deficits, and a
genomic rearrangement affecting chromosomes 7 and 11. One breakpoint mapped to 7q31 and, although outside
its coding region, was hypothesised to disrupt FOXP2 expression. We identified an element 2 kb downstream of this
breakpoint with epigenetic characteristics of an enhancer. We show that this element drives reporter gene
expression in human cell-lines. Thus, displacement of this element by translocation may disturb gene expression,
contributing to the observed language phenotype.
Mutations and chromosomal rearrangements that dis-
rupt the FOXP2 coding sequencing cause childhood
apraxia of speech (CAS) [also known as developmental
verbal dyspraxia (DVD)], as well as expressive and re-
ceptive deficits in both spoken and written language
[1–10]. Moralli et al. recently described a child with a
complex chromosomal rearrangement affecting chromo-
some 7 and 11, showing severe speech and language prob-
lems, similar to the profile typically seen for FOXP2
mutation cases [11]. For a detailed description of the
phenotype we refer to the original clinical report [11].
The rearrangement in this child consists of a pericen-
tric inversion of chromosome 7 (involving 7p15 and
7q31) and a translocation between chromosomes 7 and
11 (involving 7q21 and 11p12) [11]. The inversion and
translocation breakpoints do not interrupt the sequence
of any protein-coding genes [11]. It is therefore likely
that the observed phenotype is caused by altered expres-
sion of nearby genes. FOXP2 was considered the most
promising candidate gene, given that haploinsufficency
of this gene is known to cause speech and language dis-
orders with a similar phenotype [8]. The chromosome 7q31
breakpoint was mapped to a position 205 kb downstream
of the FOXP2 locus and 22 kb upstream of the MDFIC
gene (Fig. 1a). MDFIC expression was not significantly
different in fibroblasts taken from the proband as com-
pared to those from unaffected relatives. However,
Moralli et al. were not able to reliably determine if the
breakpoint affected FOXP2 regulation, because this
gene shows very low expression in fibroblasts.
We hypothesized that the inversion in the Moralli et
al. case would physically separate the FOXP2 coding re-
gion from a genomic element with the potential to regu-
late expression of this gene. In this letter we identify and
characterize a functional regulatory element located
>205 kb downstream of FOXP2. Our findings suggest a
mechanism by which the breakpoint could disrupt regu-
lation of FOXP2 expression and provide support for the
causative nature of this rearrangement.
To determine if the 7q31 breakpoint disrupted a regu-
latory element we used functional genomics data from
the ENCODE project [12] to predict possible enhancer
regions that would drive gene expression. Although the
reported breakpoint did not directly disrupt any pre-
dicted enhancers, we identified two possible enhancers
that are in close proximity. One element, located 2.5 kb
downstream of the breakpoint (Element 1), includes a re-
gion of open chromatin (demonstrated via DNase hyper-
sensitivity across multiple cell lines) and carries histone
modifications characteristic of an enhancer (H3K4Me1)
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[13, 14] (Fig. 1b). This genomic site has been shown to
bind several transcription factors (TF) in a colorectal
carcinoma cell line (TF ChIP; Fig. 1b), including RNA
polymerase II, which is found at transcriptional start
sites and active enhancers [15, 16]. A second candidate
region, located 12 kb downstream of the breakpoint
(Element 2), shows DNase hypersensitivity and TF
binding, but no H3K4Me1 modifications (Fig. 1b).
To test whether these regions could act as enhancer
elements we cloned them into a reporter construct in
front of a minimal promoter and luciferase reporter gene
(Fig. 1c). The resulting constructs were used to measure
the ability of each element to drive increased expression
of the reporter gene in two human cell-lines; HEK293
and SK-N-MC. Since both cell lines endogenously ex-
press FOXP2 [17] they likely express TFs that are able to
regulate this gene. Element 1, which had multiple chro-
matin signatures characteristic of an enhancer, was able
to act as a functional enhancer in both cell-lines (Fig. 1d).
In HEK293 cells we observed a 3 fold increase of luciferase
expression in comparison to the empty vector control. In




Fig. 1 Identification of functional enhancer elements downstream of the inversion breakpoint. a The genomic location of the inversion breakpoint on
chromosome 7q31 with the boundaries of the topological domain shown by green boxes [18]. Genes are depicted in blue. b Detailed view of the
breakpoint with functional annotations from the ENCODE project [12] and UCSC genome browser [20]. The inversion breakpoint was mapped to
position 114539340 of chromosome 7 in human genome build hg19 [11] (indicated by arrows). DNase hypersensitivity sites (DNase H) indicates
regions of open chromatin. The darkness of the grey boxes is proportional to maximum signal strength of the DNase hypersensitivity in any
investigated cell line. TF ChIP indicates sites that were occupied by TFs and the colour intensity is proportional to the amount of different TFs found at
one site. The H3K4Me1 track indicates the presence of histone-3 lysine-4 mono-methylation in human cell lines. Pink peaks correspond to those found
in NHEK cells (colorectal carcinoma) and orange peaks to those found in GM12878 (EBV transformed lymphoblast) cells. The investigated genomic
elements are represented as black bars. Element 1 overlaps a DNase H site detected in 48 cell lines and 4 TFs. Element 2 overlaps a DNase H
site detected in 17 cell lines and 1 TF. c-d Reporter constructs containing no enhancer (no element control), Element 1 (chr7: 114541370 – 114542201,
hg19) and Element 2 (chr 7: 114550520 – 114551429, hg19) were transfected into HEK293 and SK-N-MC cells. After 2 days the luciferase activity was
determined as described before [21]. The firefly luciferase activity was normalized to the activity of a co-transfected renilla luciferase control to
determine the relative luciferase activity. The luciferase activity driven by the genomic elements was compared to that obtained from the
control luciferase plasmid (minP). Element 1, but not Element 2 was able to enhance the activity and therefore the expression of the reporter
gene. We performed two independent experiments of each three biological replicates. Significance was determined by an ANOVA followed
by post-hoc Tukey test.*p < 0.05, ***p < 0.001. N.S.: not significant
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7 fold as compared to the control. Element 2, which
lacked histone modifications characteristic of an enhancer,
was not able to drive expression in either cell line. There-
fore, Element 1 is a functional enhancer capable of driving
increased gene expression in both human cell lines.
Thus, following fine-mapping of the breakpoint by
Moralli et al. [11], we were able to identify an active en-
hancer that is displaced by the chromosome 7 inver-
sion. Genome wide structural mapping has shown that
there are topological boundaries that regulatory ele-
ments are unlikely to cross [18]. Enhancers usually
regulate genes that lie within the same topological do-
main, suggesting 4 genes to be potentially regulated by
Element 1; PPP1R3A, FOXP2, MDFIC and TFEC. The
inversion separates Element 1 from PPP1R3A and
FOXP2. Given that PPP1R3A is a muscle specific gene
not thought to be expressed in the brain [19], we con-
sider the disrupted regulatory control of FOXP2 likely
to be a contributing factor to the phenotype found in
this proband.
In sum, our functional data provide experimental sup-
port to the theory posited in Moralli et al. [11] that the
chromosome 7 breakpoint carried by this patient con-
tributed to the speech and language phenotype by dis-
rupting the regulation of FOXP2.
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